GlassScriptPhysician profile
Latha Velusamy
NPI 1710986013
$5,008.78
in general payments reported to CMS, 2019-2025
28 companies · $509 in 2025
The $509 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2020: $184 · 2021: $372 · 2022: $905 · 2023: $1,445 · 2024: $549 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,490 · Education: $13.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,490.24 |
| Education | $13.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $658.34 | 2019-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $499.87 | 2022-2024 | Benlysta, Jesduvroq |
| Horizon Therapeutics Plc | $494.38 | 2019-2023 | Krystexxa |
| Vifor Pharma, INC. | $444.72 | 2019-2025 | Veltassa |
| Amgen INC. | $382.54 | 2019-2025 | Krystexxa, Tavneos |
| Baxter Healthcare | $367.22 | 2022-2023 | Renal - Pd |
| Akebia Therapeutics INC | $300.52 | 2019-2025 | Vafseo, Auryxia |
| Calliditas Therapeutics US INC. | $281.41 | 2022-2024 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $271.58 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $259.47 | 2022-2024 | Lupkynis |
| Travere Therapeutics, INC. | $186.12 | 2023-2025 | Filspari |
| Alexion Pharmaceuticals, INC. | $150.71 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $137.08 | 2019-2023 | Jynarque |
| Novo Nordisk INC | $80.23 | 2024-2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.71 | 2023-2025 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $63.75 | 2024-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $60.64 | 2019-2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $58.38 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $47.45 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.15 | 2020-2022 | |
| Shire North American Group INC | $28.95 | 2019 | |
| Ani Pharmaceuticals, INC. | $25.84 | 2022 | |
| Scpharmaceuticals INC. | $23.86 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $19.71 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.08 | 2025 | |
| Ardelyx, INC. | $15.57 | 2024 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $15.54 | 2024 | |
| Avenu Medical INC. | $9.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latha Velusamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.